Reported Sunday, HUTCHMED Launches Phase III Clinical Trial Of Third-Generation BTK Inhibitor HMPL-760 With R-GemOx In Chinese Relapsed/Refractory Diffuse Large B-cell Lymphoma Patients

Benzinga Newsdesk www.benzinga.com Positive 83.3%

Neg 0% Neu 0% Pos 83.3%

Comments

No comments yet. Be the first!